HIGHLIGHTS:
-
Partnership with GenesisCare to develop novel radiopharmaceuticals in Australia
-
Binding agreement to acquire Pharma15 for next generation preclinical platform of therapeutic radiopharmaceuticals – Dr Ken Herrmann joins Scientific Advisory Board
-
Initiates process for NASDAQ listing
-
Appointment of Dr. Rama Abu Shmeis as Senior Vice President, Chemistry and Manufacturing Controls
-
$1.56m R&D tax incentive received
-
Participation in Jefferies Radiopharma Innovation Summit
-
Presentation at NWR Virtual Healthcare Conference
Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to provide a summary of its activities for the quarter ended 31 March 2023.
For more information, download the attached PDF.
Download this document
